Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: International multicentre randomised trial

Lancet

Volumn 364, Issue 9441, 2004, Pages 1244-1251

  Jindani, A ^a   Nunn, A J ^b   Enarson, D A ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b Med Res Cncl Clinical Trials Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; JAUNDICE; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SAMPLE SIZE; SKIN TOXICITY; SPUTUM ANALYSIS; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; THROMBOCYTOPENIC PURPURA; TREATMENT WITHDRAWAL; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION;

EID: 3042845563     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17141-9     Document Type: Article

References (17)

1. Mitchison DA, Dickinson JM. Bactericidal mechanisms in short-course chemotherapy. Bull Int Union Tuberc. 53:1978;254-259
2. WHO/International Union Against Tuberculosis Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Geneva: WHO, 1997: WHO/TB/97.229.
3. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis: a guide for low income countries. 5th edn :2000;Compogravure Impression, Broachage Imprimerie, St-Just-La-Pendue
4. WHO. WHO report on the tuberculosis epidemic. Geneva: WHO, 1995: WHO/TB/95.
5. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 337:1991;627-630
6. WHO. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO, 2003: WHO/CDS/TB/2003.313.
7. British Medical Research Council Tuberculosis Units, 1946-1986. Studies on the treatment of tuberculosis. Int J Tuberc Lung Dis. 3 (suppl):1999;S231- S279
8. Machin D, Campbell MJ, Fayers PM, Pinol APY. Statistical tables for the design of clinical trials. 1997;Blackwell Scientific Publications, Oxford
9. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis: results up to 24 months. Tubercle. 63:1982;89-98
10. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 4:2000;796-806
11. Third East African/British Medical Research Council Study. Controlled trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: second report. Tubercle. 61:1980;59-69
12. East and Central African/British Medical Research Council Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle. 67:1986;5-15
13. Dickinson JM, Aber VR, Mitchison DA. Bacterial activity of streptomycin, isoniazid, rifampin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis. 116:1977;627-635
14. Jindani A, Doré CJ, Mitchison DA. The bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 167:2003;1348-1354
15. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 136:1987;1339-1342
16. British Thoracic Society. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis: final report, results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest. 78:1984;330-336
17. Harries AD, Gausi FK, Kwanjana JH, Nyirenda TE, Salaniponi FML. Is oral intermittent initial phase anti-tuberculosis treatment associated with higher mortality in high HIV-prevalence areas in sub-Saharan Africa? Int J Tuberc Lung Dis. 5:2001;483-485